Literature DB >> 19010231

Liver transplantation as a primary indication for intrahepatic cholangiocarcinoma: a single-center experience.

G C Sotiropoulos1, G M Kaiser, H Lang, E P Molmenti, S Beckebaum, I Fouzas, G Sgourakis, A Radtke, M Bockhorn, S Nadalin, J Treckmann, W Niebel, H A Baba, C E Broelsch, A Paul.   

Abstract

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is not a widely accepted indication for orthotopic liver transplantation (OLT). The present study describes our institutional experience with patients who underwent transplantation for ICC as well as those with ICC who underwent transplantation with the incorrect diagnosis of hepatocellular carcinoma (HCC). PATIENTS AND METHODS: Data corresponding to ICC patients were reviewed for the purposes of this study. Patients with hilar cholangiocarcinoma and incidentally found ICC after OLT for benign diseases were excluded from further consideration.
RESULTS: Among the 10 patients, 6 underwent transplantation before 1996 and 4 after 2001. Those who underwent transplantation in the early period had a preoperative diagnosis of inoperable ICC (n = 4) and ICC in the setting of primary sclerosing cholangitis (n = 2). In the latter period the subjects had a diagnosis of HCC in cirrhosis (n = 3) or recurrent ICC after an extended right hepatectomy (n = 1). Median survival was 25.3 months for the whole series and 32.2 months (range, 18-130 months) when hospital mortality was excluded (n = 3). Four patients are currently alive after 30, 35, 42, and 130 months post-OLT, respectively. Two patients died of tumor recurrence at 18 and 21 months post-OLT, respectively. One-, 3-, and 5-year survival rates were 70%, 50%, and 33%, respectively.
CONCLUSIONS: The role of OLT in the setting of ICC may be re-evaluated in the future under strict selection criteria and with prospective multicenter randomized studies. Potential candidates to be included are those with liver cirrhosis and no hilar involvement who meet the Milan criteria for HCC.

Entities:  

Mesh:

Year:  2008        PMID: 19010231     DOI: 10.1016/j.transproceed.2008.08.053

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  15 in total

1.  Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies.

Authors:  Sonja K Olsen; Robert S Brown; Abby B Siegel
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

2.  Clinicopathological and prognostic analysis of 429 patients with intrahepatic cholangiocarcinoma.

Authors:  Wei-Feng Shen; Wei Zhong; Feng Xu; Tong Kan; Li Geng; Feng Xie; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

Review 3.  Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009.

Authors:  Murad Aljiffry; Mark J Walsh; Michele Molinari
Journal:  World J Gastroenterol       Date:  2009-09-14       Impact factor: 5.742

4.  Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study.

Authors:  W F Shen; W Zhong; Q Liu; C J Sui; Y Q Huang; J M Yang
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

Review 5.  Surgical options for intrahepatic cholangiocarcinoma.

Authors:  Kui Wang; Han Zhang; Yong Xia; Jian Liu; Feng Shen
Journal:  Hepatobiliary Surg Nutr       Date:  2017-04       Impact factor: 7.293

Review 6.  Epidemiology and surgical management of intrahepatic cholangiocarcinoma.

Authors:  Han Zhang; Feng Shen; Jun Han; Yi-Nan Shen; Guo-Qiang Xie; Meng-Chao Wu; Tian Yang
Journal:  Hepat Oncol       Date:  2015-11-30

7.  Liver transplantation for hilar cholangiocarcinoma--a single-centre experience.

Authors:  Silke Schüle; Annelore Altendorf-Hofmann; Frank Uteß; Falk Rauchfuß; Martin Freesmeyer; Thomas Knösel; Yves Dittmar; Utz Settmacher
Journal:  Langenbecks Arch Surg       Date:  2012-10-09       Impact factor: 3.445

Review 8.  The treatment of cholangiocarcinoma: a hepatologist's perspective.

Authors:  Kamran Qureshi; Randhir Jesudoss; Abdullah M S Al-Osaimi
Journal:  Curr Gastroenterol Rep       Date:  2014-10

Review 9.  Cholangiocarcinoma: has there been any progress?

Authors:  Judith Meza-Junco; Aldo J Montano-Loza; Mang Ma; Winnie Wong; Michael B Sawyer; Vincent G Bain
Journal:  Can J Gastroenterol       Date:  2010-01       Impact factor: 3.522

Review 10.  Update on the Diagnosis and Treatment of Cholangiocarcinoma.

Authors:  Bryan Doherty; Vinod E Nambudiri; William C Palmer
Journal:  Curr Gastroenterol Rep       Date:  2017-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.